TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35924472

Group type: EXPERIMENTAL
Intervention: ME group (ablation using mini-electrode catheters)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (ablation using conventional catheters)
Number of subjects: 136
Study: 34191033

Group type: EXPERIMENTAL
Intervention: NAD+-precursor supplementation (207.5 mg niacin equivalents/day) for 32 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: NAD+-precursor supplementation
Number of subjects: 14
Study: 32435772

Group type: EXPERIMENTAL
Intervention: Treatment with chitosan nanoparticles (Csnp) solution under ultrasonic agitation for 60 s and immersed in EDC crosslinker for 24 h
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Immersion in 2.5% glutaraldehyde for 24 h
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (without treatment)
Number of subjects: 48
Study: 35219335

Group type: EXPERIMENTAL
Intervention: Bilateral ankle exoskeletons
Number of subjects: 10
Study: 34444843

Group type: EXPERIMENTAL
Intervention: Arabinoxylan (AX)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 239
Study: 32522244

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg orally two times per day for 10 days (n = 140)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Benzathine penicillin G 2.4 million units intramuscularly based on the stage of syphilis infection (n = 70)
Number of subjects: 210
Study: 36445170

Group type: EXPERIMENTAL
Intervention: Telehealth training group (TR) - systematic physical and cognitive exercises, 50-min sessions, three times a week for 12 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (CG) - non-systematized guidance for 12 weeks
Number of subjects: 78
Study: 32977975

Group type: EXPERIMENTAL
Intervention: As-needed acetaminophen + codeine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Scheduled acetaminophen/as-needed tramadol
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 126
Study: 33019274

Group type: EXPERIMENTAL
Intervention: Smartwatch group (intervention)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Handwashing group (control)
Number of subjects: 120
Study: 35784564

Group type: EXPERIMENTAL
Intervention: MMI combined with Se and VitD
Number of subjects: 42

Group type: COMPARATOR
Intervention: MMI monotherapy
Number of subjects: 42
Study: 34627265

Group type: EXPERIMENTAL
Intervention: Multiple stent (MS) group
Number of subjects: 168
Study: 35123569

Group type: EXPERIMENTAL
Intervention: Internet-supported mindfulness-based cognitive therapy (MBCT) for 8 weeks with weekly group sessions via videoconference, asynchronous homework, an online retreat after the fifth week, and 4 monthly booster sessions after completion of the 8-week programme.
Number of subjects: 111

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 111
Study: 33314545

Group type: EXPERIMENTAL
Intervention: Real continuous theta-burst stimulation (cTBS) on the left supplementary motor area (SMA) for 14 consecutive days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham continuous theta-burst stimulation (cTBS)
Number of subjects: 42
Study: 33068295

Group type: EXPERIMENTAL
Intervention: CFC-health questionnaire
Number of subjects: 1001

Group type: COMPARATOR
Intervention: CFC-general questionnaire
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: CFC-I and CFC-F dimensions
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Self-evaluated health behaviors
Number of subjects: 1001
Study: 35725576

Group type: EXPERIMENTAL
Intervention: C-PPRS (Chinese version of the Perceived Partner Responsiveness Scale)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: C-PPRS
Number of subjects: 441
Study: 34139272

Group type: EXPERIMENTAL
Intervention: Nivolumab with carboplatin, paclitaxel, and bevacizumab
Number of subjects: 550

Group type: COMPARATOR
Intervention: Placebo with carboplatin, paclitaxel, and bevacizumab
Number of subjects: 550
Study: 35868146

Group type: EXPERIMENTAL
Intervention: Once-weekly LAGH (0.7 mg/kg/week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Daily GH (0.37 mg/kg/week)
Number of subjects: 10
Study: 32645310

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of mitomycin C (MMC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Direct scleral application of mitomycin C (MMC)
Number of subjects: 100
Study: 33108247

Group type: EXPERIMENTAL
Intervention: Medication Adherence Report Scale (MARS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis (CFA) of MARS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MARS compared with caregiver-reported medication adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MARS compared with Asthma Medication Ratio (AMR), asthma control, and caregiver perception of asthma control
Number of subjects: 0
Study: 35320964

Group type: EXPERIMENTAL
Intervention: Intrathecal 3 mg hyperbaric bupivacaine 0.5% plus 20 microgram fentanyl and intravenous fentanyl at 1μg.kg(‐1).h(‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous fentanyl at 1μg.kg(‐1).h(‐1) and laparoscopic port site infiltration with 0.5% bupivacaine
Number of subjects: 100
Study: 35026053

Group type: EXPERIMENTAL
Intervention: Group Music Therapy (GMT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Recreational Choir Singing (RCS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Therapeutic music interventions
Number of subjects: 24
Study: 35422056

Group type: EXPERIMENTAL
Intervention: Doubling practice of calligraphy (2 hours per week)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual practice of calligraphy (1 hour per week)
Number of subjects: 112
Study: 33564230

Group type: EXPERIMENTAL
Intervention: Calcium fructoborate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35929466

Group type: EXPERIMENTAL
Intervention: Fluoxetine intervention
Number of subjects: 1280

Group type: COMPARATOR
Intervention: No fluoxetine intervention (Control)
Number of subjects: 1280
Study: 32702298

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Number of subjects: 1077

Group type: COMPARATOR
Intervention: MenACWY
Number of subjects: 1077
Study: 32465125

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 81
Study: 36380693

Group type: EXPERIMENTAL
Intervention: Tofacitinib (10 mg/bid for 2 weeks)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 116
Study: 34470599

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation at 400 IU/day
Number of subjects: 87

Group type: COMPARATOR
Intervention: No vitamin D supplementation (control)
Number of subjects: 87
Study: 32485656

Group type: EXPERIMENTAL
Intervention: 60 mg MAS-ER
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 80 mg MAS-ER
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 35331698

Group type: EXPERIMENTAL
Intervention: PCV10 intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold effects
Number of subjects: 0
Study: 32330749

Group type: COMPARATOR
Intervention: Fast Food (FF) diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mediterranean (Med) diet
Number of subjects: 10
Study: 34966061

Group type: EXPERIMENTAL
Intervention: Home-based meditative practices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adapted training protocol for recruiters and interveners
Number of subjects: 0
Study: 32147329

Group type: EXPERIMENTAL
Intervention: Type 1 brackets with black tea
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Type 1 brackets with Cola
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Type 2 brackets with black tea
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Type 2 brackets with Cola
Number of subjects: 40
Study: 34299807

Group type: EXPERIMENTAL
Intervention: Limiting/monitoring screen time (ST)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Exposure to TV
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Parent use of ST as a reward
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Limiting/monitoring ST
Number of subjects: 252
Study: 36242996

Group type: EXPERIMENTAL
Intervention: #Tamojunto2.0 program
Number of subjects: 5208

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5208

Group type: EXPERIMENTAL
Intervention: Users group
Number of subjects: 5208
Study: 32580919

Group type: EXPERIMENTAL
Intervention: ccIIV4 (Flucelvax®)
Number of subjects: 144

Group type: COMPARATOR
Intervention: IIV4 (Fluzone ®)
Number of subjects: 144
Study: 34463759

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) at four specific AA points (knee joint, shenmen, subcortex, and sympathesis)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham auricular acupressure (non-acupuncture points on the auricular helix)
Number of subjects: 62
Study: 33498445

Group type: EXPERIMENTAL
Intervention: Fish fed with fish oil diet (conventional fish, CF)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Fish fed with olive pomace-enriched diet (enriched fish, EF)
Number of subjects: 38
Study: 32208351

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (3 cycles of epirubicin, cisplatin or oxaliplatin and capecitabine) followed by surgery and either postoperative chemotherapy or chemoradiotherapy (45Gy + cisplatin + capecitabine)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy
Number of subjects: 788
Study: 34480630

Group type: EXPERIMENTAL
Intervention: Cannabidiol 600 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 34256130

Group type: EXPERIMENTAL
Intervention: Assisted ventilation with maximum airway pressure
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dorsal recumbency
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Maximum airway pressure
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) scanning at a range of end‐inspiratory pressures
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Static compliance of the lungs
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Assisted ventilation at 10 cmH2O at 4 breaths min−1
Number of subjects: 9
Study: 34818074

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise for 25-40 min on 3-4 days per week for 14 ± 1 wk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute exercise (sit-to-stand maneuver)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic exercise (exercise training)
Number of subjects: 0
Study: 32986652

Group type: EXPERIMENTAL
Intervention: Neuromuscular stabilization technique (NST), performed for an average of 30 min per session, three times a week for six months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group received education for a home exercise program
Number of subjects: 20
Study: 32666638

Group type: EXPERIMENTAL
Intervention: Psychological nursing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care (Control)
Number of subjects: 0
Study: 34902752

Group type: EXPERIMENTAL
Intervention: Endo-TLIF
Number of subjects: 102

Group type: COMPARATOR
Intervention: MIS-TLIF
Number of subjects: 102
Study: 33664007

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 32785587

Group type: EXPERIMENTAL
Intervention: Total consumption questions
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Location-specific peak consumption questions (LSPC)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Location-specific peak consumption questions (LSPC) first for heavy drinkers in the highest tercile
Number of subjects: 274
Study: 35905339

Group type: EXPERIMENTAL
Intervention: Randomized phase estimation algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous L‐independent approaches (e.g., qDRIFT)
Number of subjects: 0
Study: 32666349

Group type: EXPERIMENTAL
Intervention: Probiotic gel and lozenges (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study: 36191882

Group type: EXPERIMENTAL
Intervention: Adebrelimab (20 mg/kg on day 1), nab-paclitaxel (100 mg/m2 on days 1, 8, and 15), and carboplatin (AUC 5 mg/mL per min on day 1) as neoadjuvant treatment followed by 16 cycles of adebrelimab (20 mg/kg on day 1 every 3 weeks) as adjuvant treatment.
Number of subjects: 37
Study: 33951024

Group type: COMPARATOR
Intervention: Indwelling analgesic catheter (IC)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Single dose liposomal bupivacaine (LB)
Number of subjects: 34
Study: 32648394

Group type: EXPERIMENTAL
Intervention: Herb-separated moxibustion applied at hypogastrium and lumbosacral area for 30 min, once a week for 3 months.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waiting-list group (no intervention except ibuprofen when necessary).
Number of subjects: 54
Study: 35552166

Group type: EXPERIMENTAL
Intervention: Tailoring+Fitbit
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Tailoring only
Number of subjects: 243

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 243
Study: 34098037

Group type: EXPERIMENTAL
Intervention: The Illicit Project program (a three-lesson, web-based program delivered fortnightly over 6 weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Health education as usual (control group)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: The Illicit Project program
Number of subjects: 8
Study: 32251303

Group type: EXPERIMENTAL
Intervention: Dietary restriction (DR) - formula diet containing 60% of daily energy requirement during the 4-day interval before PCI
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Dietary restriction (DR) - formula diet containing 60% of daily energy requirement
Number of subjects: 108
Study: 34511586

Group type: EXPERIMENTAL
Intervention: IV OPC‐61815 16 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral tolvaptan 15 mg
Number of subjects: 60
Study: 32001003

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Short-term Psychodynamic Psychotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Naturalistic controls (treatment as usual)
Number of subjects: 75
Study: 36309660

Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Venturi Mask (VM)
Number of subjects: 35
Study: 34085505

Group type: EXPERIMENTAL
Intervention: TRIOS group (digital impressions using Trios Pod Scanner)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CEREC group (digital impressions using Cerec AC Omnicam)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (conventional impressions using polyvinyl siloxane silicone material)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups (comparison of continuous margin evaluations)
Number of subjects: 24
Study: 33449534

Group type: EXPERIMENTAL
Intervention: Amantadine sulfate (400 mg/day intravenously for 4 days, followed by oral administration at 400 mg/day for 6 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard therapy according to the order of the Ministry of Health of the Russian Federation No. 928n
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Amantadine sulfate
Number of subjects: 95
Study: 35715574

Group type: EXPERIMENTAL
Intervention: Anodal TDCS (2 mA, 20 min) on intact SMG
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham TDCS (30 s, 5 sessions)
Number of subjects: 44
Study: 34967830

Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control (riboflavin ophthalmic solution)
Number of subjects: 0
Study: 32369007

Group type: EXPERIMENTAL
Intervention: Computerised speech and language therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 240
Study: 35870491

Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: UT‐DSAEK
Number of subjects: 50
Study: 34179925

Group type: COMPARATOR
Intervention: Exercise group (E)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Exercise plus high-protein group (EP)
Number of subjects: 69
Study: 33128502

Group type: EXPERIMENTAL
Intervention: Egg group (1 egg per day for 6 months)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 660
Study: 34399136

Group type: EXPERIMENTAL
Intervention: Video directly observed therapy (DOT) using a HIPAA-compliant smartphone application
Number of subjects: 78

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 78
Study: 35427407

Group type: EXPERIMENTAL
Intervention: Dominant members (D)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Adductors
Number of subjects: 23
Study: 33528004

Group type: EXPERIMENTAL
Intervention: Tailored Therapeutic Exercise and Recovery Strategies (ATOPE) program, performed before treatment, with 12 to 18 sessions of tailored, high‐intensity exercise and post‐exercise recovery strategies.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tailored Therapeutic Exercise and Recovery Strategies (ATOPE) program
Number of subjects: 120
Study: 32861537

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 35422139

Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Computer-aided design NAM (CAD/NAM)
Number of subjects: 30
Study: 33612068

Group type: EXPERIMENTAL
Intervention: PSA-test; if PSA ≥ 3 ng/mL, then MRI and systematic biopsy, plus targeted biopsy to suspicious lesions as per PI-RADSv2 3–5
Number of subjects: 38770

Group type: EXPERIMENTAL
Intervention: PSA-test; if PSA ≥ 3 ng/mL, then MRI, and targeted biopsy only if PI-RADSv2 3–5
Number of subjects: 38770

Group type: EXPERIMENTAL
Intervention: Identical to Arm 2, except lower PSA-cut-off ≥1.8 ng/mL
Number of subjects: 38770

Group type: COMPARATOR
Intervention: PSA-screening and systematic biopsy
Number of subjects: 38770
Study: 32307933

Group type: EXPERIMENTAL
Intervention: LIPUS therapy combined with Twin-Block appliance
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Twin-Block appliance only
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (observational, no treatment)
Number of subjects: 45
Study: 35155721

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 50
Study: 32366163

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: TMAO quartile 4
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: TMAO quartile 4 after adjustment for clinical factors
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: TMAO quartile 4 after adjustment for cardiovascular biomarkers
Number of subjects: 1803
Study: 35862001

Group type: EXPERIMENTAL
Intervention: Isocaloric multifactorial diet rich in MUFA, polyunsaturated fatty acids, fiber, polyphenols, and vitamins (n = 18)
Number of subjects: 39

Group type: COMPARATOR
Intervention: MUFA-rich diet (n = 21)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Isocaloric multifactorial diet
Number of subjects: 39

Group type: COMPARATOR
Intervention: MUFA-rich diet
Number of subjects: 39
Study: 34028967

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg daily plus 177Lu-PSMA-617 7.5 GBq on Days 15 and 57 (up to four doses total)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Enzalutamide 160 mg daily alone
Number of subjects: 160
Study: 32618249

Group type: COMPARATOR
Intervention: Standard of care (SoC) malaria interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SoC plus focal mass drug administration (fMDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SoC plus mass drug administration (MDA)
Number of subjects: 0
Study: 35545875

Group type: COMPARATOR
Intervention: Topical product (Group C) - cream formulation containing hydroxypinacolone/retinyl palmitate, Iris Florentina root extract, and a complex of three oligopeptides applied twice a day.
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Combination treatment (Group C + O) - topical product plus prebiotic food supplement (FOS&GOS, zinc, lactoferrin, niacinamide).
Number of subjects: 184
Study: 34692934

Group type: EXPERIMENTAL
Intervention: Hydrotherapy group (HT) with innovative aquatic proprioceptive training plus conventional rehabilitation for 6 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional therapy group (CT) with conventional rehabilitation for 6 weeks
Number of subjects: 38
Study: 35178237

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MA) with CT monitoring
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MA) with MRI monitoring
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison of inactivation rates between CT and MRI groups
Number of subjects: 96
Study: 33677771

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) alone
Number of subjects: 218

Group type: COMPARATOR
Intervention: Pegylated interferon alpha2a (Peg‐IFN‐α‐2a) add‐on
Number of subjects: 218
Study: 32122311

Group type: EXPERIMENTAL
Intervention: HOME intervention (patient-centered discharge planning led by an occupational therapist)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: HOME intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Structured in-hospital consultation (Control)
Number of subjects: 400
Study: 34749418

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Interval Training (MIIT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 38
Study: 32972478

Group type: EXPERIMENTAL
Intervention: Group PBCT within SVC
Number of subjects: 95

Group type: COMPARATOR
Intervention: Routine clinical practice (SVC)
Number of subjects: 95
Study: 32251265

Group type: EXPERIMENTAL
Intervention: GFAP + prehospital characteristics (PH)
Number of subjects: 243